<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00261417</url>
  </required_header>
  <id_info>
    <org_study_id>D6160L00001</org_study_id>
    <secondary_id>SH-SBD-0013</secondary_id>
    <nct_id>NCT00261417</nct_id>
  </id_info>
  <brief_title>Dose Response Study in Japanese Patients</brief_title>
  <official_title>A Randomized, Double-Blind, Multicentre, Placebo-Controlled Study to Evaluate the Efficacy, Dose-Response and Safety of Tesaglitazar Therapy in Japanese Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This is a 12-week study to determine the effect on glucose and lipids, safety, and&#xD;
      tolerability of four doses of tesaglitazar (0.25, 0.5, 0.75 and 1 mg) compared with placebo&#xD;
      in patients with type 2 diabetes. Improvement in dyslipidemia will be evaluated. The study&#xD;
      comprises a 2-week screening period, 4-week placebo run-in, a 12-week randomized, double&#xD;
      blind, parallel group, multi-center, placebo-controlled treatment period, and a 3-week&#xD;
      follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The development program has been terminated&#xD;
  </why_stopped>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-response relationship of tesaglitazar in subjects with type 2 diabetes by the assessment of the effects of each of four doses of tesaglitazar (0.25, 0.5, 0.75 and 1 mg) to placebo with respect to fasting plasma glucose</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the following variables from baseline to the end of the randomized treatment period:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, total cholesterol apolipoproteins (Apo) (Apo A-I, Apo B and Apo CIII), and f</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose and insulin values during an oral glucose tolerance test</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on the reduction of insulin and glycosylated hemoglobin A1c levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on the proportion of fasting plasma glucose responders</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on the proportion of high-density lipoprotein cholesterol responders</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on the changes from baseline in weight and waist/hip ratio</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pharmacokinetics of tesaglitazar</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the safety and tolerability of tesaglitazar compared to placebo</measure>
  </secondary_outcome>
  <enrollment>250</enrollment>
  <condition>Type 2 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesaglitazar</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of a written informed consent&#xD;
&#xD;
          -  Men or women who are &gt;=18 years of age&#xD;
&#xD;
          -  Female patients: postmenopausal, hysterectomized&#xD;
&#xD;
          -  Diagnosed with type 2 diabetes&#xD;
&#xD;
          -  Treated with diet alone or treatment with a single oral antidiabetic agent or low&#xD;
             doses of two oral anti-diabetic agents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  New York Heart Association heart failure Class III or IV&#xD;
&#xD;
          -  Treatment with chronic insulin&#xD;
&#xD;
          -  History of hypersensitivity or intolerance to any peroxisome proliferator-activated&#xD;
             receptor agonist (like Actos or Avandia), fenofibrate, metformin or&#xD;
             3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)&#xD;
&#xD;
          -  History of drug-induced myopathy or drug-induced creatine kinase elevation, liver&#xD;
             enzyme elevations, neutropenia (low white blood cells)&#xD;
&#xD;
          -  Creatinine levels above twice the normal range&#xD;
&#xD;
          -  Creatine kinase above 3 times the upper limit of normal&#xD;
&#xD;
          -  Received any investigational product in other clinical studies within 12 weeks&#xD;
&#xD;
          -  Any clinically significant abnormality identified on physical examination, laboratory&#xD;
             tests or electrocardiogram, which in the judgment of the investigator would compromise&#xD;
             the patient's safety or successful participation in the clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Japan Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashino</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fuchu Keijinkai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fujimino</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hijirino Koike</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houseikai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyuga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iriuchijima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iwase</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kato</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawamata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Keishukai Shirakawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kouhoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kousei</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kurosawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nihonmatu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saiseikai Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takamori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>December 1, 2005</study_first_submitted>
  <study_first_submitted_qc>December 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2005</study_first_posted>
  <last_update_submitted>April 21, 2009</last_update_submitted>
  <last_update_submitted_qc>April 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

